Skip to main content

2.

2

Kaplan-Meier estimates of progression-free survival (PFS) in months for triple-negative breast cancer (TNBC) patients. (A) PFS for patients with circulating tumor cell (CTC) positivity (>2CTC/2 mL of whole blood) compared to those with CTC negativity (≤2CTC/2 mL of whole blood) at baseline in total TNBC patients (P=0.118); (B) PFS for patients with CTC positivity compared to those with CTC negativity at baseline in patients who received first line therapy (P=0.033).